Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)

NCT00242320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

551

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Roflumilast
DRUG: Placebo

Sponsor

AstraZeneca